Fisetin Supplement Market Report 2026

Market snapshot

The Phase 3 dataset contains 21 current entries. 12 are categorized as single-ingredient or single-ingredient high-dose products. Captured bottle prices range from $11.25 to $95.0, with a median of $37.95. Declared fisetin amounts were captured for 18 products, spanning 8.0 mg to 1500.0 mg. Those ranges show why one-dimensional “best fisetin” lists are weak: the market is not selling one standardized object.

What the distribution suggests

The product set mixes low-dose conventional capsules, high-dose offerings, enhanced-bioavailability positioning and multi-active combinations. A shopper comparing only headline milligrams can easily compare unlike products. Phase 4 therefore treats format, serving basis, additional actives and documentation as separate fields. This makes the dataset more useful for citation and for buyer due diligence without pretending that commercial variety equals scientific validation.

What this report measures

This Phase 4 report converts the Senolytic Report product database into a citation-friendly market snapshot. The database currently tracks 21 products. Fields include declared fisetin amount, serving design, container size, current captured price, delivery format, third-party testing visibility, certificate-of-analysis visibility, GMP information, additional actives and editorial scores for transparency, evidence match, stack complexity and fisetin value. The report does not turn those fields into a claim of clinical superiority. Its purpose is narrower: make the commercial landscape easier to audit and easier to cite.

Why market data needs a methodology

Supplement markets are full of incomplete labels, stale retailer snippets and brand claims that change faster than most comparison articles. The database therefore records missing information as not captured instead of silently filling gaps. That distinction matters. “Not captured” is not the same as “no testing exists,” and a visible COA is not the same as proof that a supplement produces a health outcome. The methodology separates product-documentation questions from clinical-evidence questions so the reader can see what is known and what remains uncertain.

Evidence match is not an efficacy score

The Evidence Match metric asks how easily the commercial product can be related to the material, dose or formulation discussed in published research. A simple, clearly dosed fisetin capsule may be easier to map to ingredient-level evidence than a complex formula containing several compounds at unclear amounts. That does not prove the simpler product works better. It means there are fewer assumptions when connecting the label to the research. Finished formulas should not inherit the strongest ingredient-level evidence automatically.

Transparency is commercially useful even when efficacy is unknown

The median transparency score in the captured dataset is 6.0/10. Transparency covers practical auditability rather than clinical outcome. A buyer benefits when serving size, ingredient quantity, testing statements, manufacturer identity and documentation can be checked without guesswork. A low score does not prove a product is unsafe, and a high score does not prove it is effective. The score exists because commercial uncertainty is itself a meaningful buying variable.

Price requires normalization

The captured median bottle price is $37.95, but bottle price alone is a poor comparison. Products differ in fisetin quantity, serving count, delivery format and the number of additional actives. Where comparable fisetin amounts were available, the median captured cost per 100 mg was $21.84. That number is useful as context, not as a winner generator. A cheaper cost per 100 mg can coexist with weaker documentation, a less convenient serving design or a formula that is harder to relate to published evidence.

What readers should not infer

This report should not be read as evidence that fisetin removes senescent cells in humans, reverses aging, treats disease or guarantees a longevity outcome. Senolytic research spans cell models, animals, mechanisms and a smaller human evidence base. Those layers cannot be collapsed into one conclusion. A commercial market report can show what products claim and how they are documented. It cannot convert a promising mechanism into a proven consumer outcome.

How to use the snapshot

Use this report as a starting point for product due diligence. Confirm the current manufacturer page, serving size, exact active amount, other ingredients, testing documents, price, subscription terms and return policy. If a product uses high doses, unusual pulse protocols or a multi-ingredient stack, the gap between general research context and individual use becomes more important. Buyers taking medication or managing a medical condition should involve a qualified health professional rather than treating a market table as personal dosing advice.

Update policy

The market is reviewed as a dated snapshot. Price, formulation, COA availability, testing language and even whether a product remains on sale can change. Phase 4 therefore makes the date visible and keeps the scoring methodology separate from efficacy claims. When a source cannot be verified, the field should remain unverified instead of being reconstructed from memory or marketing copy. That makes the dataset less tidy, but more honest. Apparently reality refuses to organize itself for SEO convenience.

Dataset snapshot

How the dataset supports reproducibility

A market report becomes more useful when another reader can understand how the underlying number was produced. Senolytic Report therefore keeps product-level fields separate from report-level interpretation. The product count comes from the current database snapshot, pricing statistics come only from entries with a captured price, and dose statistics come only from rows where a fisetin amount is available. Missing fields are not silently converted to zero. This prevents a clean-looking average from hiding incomplete commercial information and gives later updates a consistent baseline.

Why product categories are kept separate

Single-ingredient fisetin, high-dose fisetin, liposomal formats and broad multi-active stacks may appear in the same shopping search, but they are not equivalent commercial objects. Category labels help prevent accidental comparisons between products with different purposes and serving logic. The report can still summarize the overall market, but a careful reader should move from the market-level number back to the product category before making a decision. This is particularly important when price-per-milligram looks attractive only because the formula or serving basis is different.

Related research

• Database
• Database/Fisetin Value Index
• Database/Testing Transparency
• Editorial Methodology